HUTCHMED (China) Limited is a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. The company has built fully integrated capabilities encompassing early-stage research, clinical development, manufacturing, and commercialization to advance its portfolio of novel cancer and immunology therapies while maintaining a strong operational presence in key markets.

HUTCHMED (China) Limited generates revenue primarily through the sale of its commercialized oncology drugs. In 2025, the company reported $76.9 million in revenue from Elunate (fruquintinib in China), $89.4 million from Fruzaqla (fruquintinib outside China), $18.6 million from Orpathys (savolitinib), $27.0 million from Sulanda (surufatinib), and $2.5 million from Tazverik (tazemetostat). Additionally, the company earns revenue from royalty payments, manufacturing services, and milestone payments tied to its strategic partnerships with AstraZeneca, Eli Lilly, and Takeda. Its Other Ventures segment contributes significant revenue from drug marketing and distribution activities in China, with consolidated revenue of $263.0 million in 2025.

The company operates through the following segments: Oncology/Immunology and Other Ventures.

• Oncology/Immunology: This segment focuses on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It has successfully brought four drugs to market: savolitinib (Orpathys) for non-small cell lung cancer, fruquintinib (Elunate/Fruzaqla) for colorectal cancer, surufatinib (Sulanda) for neuroendocrine tumors, and tazemetostat (Tazverik) for follicular lymphoma. The segment maintains a robust pipeline of clinical-stage candidates targeting various biological pathways, including MET, VEGFR, FGFR, and other kinases, and leverages strategic partnerships with AstraZeneca for savolitinib, Eli Lilly for fruquintinib in China, and Takeda for fruquintinib outside China.

• Other Ventures: This segment encompasses the company's drug marketing and distribution platforms in China, including its Distribution Business (51% owned with Sinopharm holding 49%) and its residual 5% interest in Shanghai Hutchison Pharmaceuticals following the divestment of a 45% stake in April 2025. The segment focuses on the sale of prescription drugs, providing logistics services, marketing, and distribution to hospitals, clinics, and through distributor networks across China.

HUTCHMED (China) Limited positions itself as an innovative leader in oncology and immunology drug development, leveraging its proprietary discovery engine to create first-in-class therapies with high selectivity and favorable safety profiles. The company believes its differentiated approach, which emphasizes minimizing off-target toxicities and enabling combination therapies, provides a competitive advantage in a crowded market. While it faces competition from major pharmaceutical and biotechnology firms developing similar targeted therapies, HUTCHMED's early success with drugs like savolitinib—the first selective MET inhibitor approved in China—demonstrates its ability to innovate. The company continues to invest heavily in research and development to sustain its pipeline of novel candidates and expand its global footprint through strategic alliances.

The company serves patients with cancer and immunological diseases globally through its commercialized drugs, which are made available via partnerships with international pharmaceutical companies and direct commercialization in key markets. In China, its Oncology/Immunology segment works closely with partners like AstraZeneca, Eli Lilly, and Takeda to bring therapies to patients, while its Other Ventures segment focuses on the domestic distribution of prescription drugs. Specifically, the Other Ventures segment sells products directly to hospitals and clinics in China and utilizes a network of distributors to reach broader markets, with key partners including Sinopharm in its Distribution Business joint venture. Major oncology partners include AstraZeneca for savolitinib, Eli Lilly for fruquintinib in China, and Takeda for fruquintinib outside China.